Costs and cost effectiveness of low molecular weight heparins and platelet glycoprotein IIb/IIIa inhibitors Nick BosanquetBengt JönssonKeith A. A. Fox Original Research Article 22 September 2012 Pages: 1135 - 1152
Cost-utility analysis of survival with epoetin-alfa versus placebo in stage IV breast cancer Silas C. MartinDennis D. GagnonBen van Hout Original Research Article 22 September 2012 Pages: 1153 - 1169
The cost effectiveness of Apligraf® treatment of diabetic foot ulcers W. Ken RedekopJoseph McDonnellZoltan Kalo Original Research Article 22 September 2012 Pages: 1171 - 1183
Escitalopram Katherine F. CroomGreg L. Plosker Original Research Article 22 September 2012 Pages: 1185 - 1209
Pharmaceutical expenditure and therapeutic value of new medicines in Spain Josep Darba Correspondence 22 September 2012 Pages: 1211 - 1212